Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume Increase – What’s Next?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) saw an uptick in trading volume on Wednesday . 3,050,666 shares traded hands during mid-day trading, an increase of 90% from the previous session’s volume of 1,607,597 shares.The stock last traded at $22.79 and had previously closed at $22.92.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CNTA. Stephens began coverage on Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 price objective for the company. Truist Financial boosted their price target on shares of Centessa Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 27th. Chardan Capital restated a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Finally, Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Centessa Pharmaceuticals Price Performance

The company has a market cap of $3.12 billion, a price-to-earnings ratio of -12.69 and a beta of 1.56. The company has a 50-day simple moving average of $25.96 and a 200-day simple moving average of $21.88. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). As a group, research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, CTO Tia L. Bush sold 40,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the sale, the chief technology officer owned 121,503 shares in the company, valued at $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mario Alberto Accardi sold 10,000 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the transaction, the insider owned 178,801 shares in the company, valued at $5,364,030. This trade represents a 5.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 58,000 shares of company stock valued at $1,540,000 in the last three months. 7.09% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Avoro Capital Advisors LLC raised its position in shares of Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after buying an additional 5,808,080 shares during the period. Federated Hermes Inc. acquired a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at $42,429,000. Adage Capital Partners GP L.L.C. boosted its position in Centessa Pharmaceuticals by 20.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock worth $110,415,000 after purchasing an additional 1,449,000 shares during the period. Balyasny Asset Management L.P. acquired a new stake in Centessa Pharmaceuticals in the 2nd quarter valued at $16,052,000. Finally, Commodore Capital LP lifted its stake in shares of Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after purchasing an additional 930,711 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.